Skip Nav Destination
Issues
1 May 2020
-
Cover Image
Cover Image
In this issue, Zenke and colleagues introduce a novel pharmacological DNA-PK inhibitor M3814 (peposertib). M3814 blocks the repair of DNA double strand breaks, potently sensitizes cancer cells to radiation and regresses human tumor in mouse models of radiation therapy. The image shows that M3814 effectively prolongs the life of radiation-induced double strand breaks in FaDu xenograft tumors when given orally to nude mice. The abundant nuclear staining of γH2AX, as seen in this image, is indicative of unrepaired double strand breaks. Read the full article on page 1091. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1535-7163
EISSN 1538-8514
Highlights
Small Molecule Therapeutics
Author Choice
Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models
Frank T. Zenke; Astrid Zimmermann; Christian Sirrenberg; Heike Dahmen; Vladimir Kirkin; Ulrich Pehl; Thomas Grombacher; Claudia Wilm; Thomas Fuchss; Christiane Amendt; Lyubomir T. Vassilev; Andree Blaukat
Decitabine Response in Breast Cancer Requires Efficient Drug Processing and Is Not Limited by Multidrug Resistance
Margaret L. Dahn; Brianne M. Cruickshank; Ainsleigh J. Jackson; Cheryl Dean; Ryan W. Holloway; Steven R. Hall; Krysta M. Coyle; Hillary Maillet; David M. Waisman; Kerry B. Goralski; Carman A. Giacomantonio; Ian C.G. Weaver; Paola Marcato
Author Choice
Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis–Initiating Cells
Daisuke Yamashita; Mutsuko Minata; Ahmed N. Ibrahim; Shinobu Yamaguchi; Vito Coviello; Joshua D. Bernstock; Shuko Harada; Richard A. Cerione; Bakhos A. Tannous; Concettina La Motta; Ichiro Nakano
Large Molecule Therapeutics
Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy
Vincenza Conteduca; Sheng-Yu Ku; Loredana Puca; Megan Slade; Luisa Fernandez; Judy Hess; Rohan Bareja; Panagiotis J. Vlachostergios; Michael Sigouros; Juan Miguel Mosquera; Andrea Sboner; David M. Nanus; Olivier Elemento; Ryan Dittamore; Scott T. Tagawa; Himisha Beltran
Author Choice
Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies
Roman Groisberg; Jason Roszik; Anthony P. Conley; Alexander J. Lazar; Daniella E. Portal; David S. Hong; Aung Naing; Cynthia E. Herzog; Neeta Somaiah; Maria A. Zarzour; Shreyaskumar Patel; Robert E. Brown; Vivek Subbiah
Cancer Biology and Translational Studies
CDK9 Blockade Exploits Context-dependent Transcriptional Changes to Improve Activity and Limit Toxicity of Mithramycin for Ewing Sarcoma
Guillermo Flores; Joel H. Everett; Elissa A. Boguslawski; Brandon M. Oswald; Zachary B. Madaj; Ian Beddows; Sergey Dikalov; Marie Adams; Carleen A. Klumpp-Thomas; Susan M. Kitchen-Goosen; Scott E. Martin; Natasha J. Caplen; Lee J. Helman; Patrick J. Grohar
Author Choice
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors
John H. Strickler; Patricia LoRusso; Ravi Salgia; Yoon-Koo Kang; Chia Jui Yen; Chia-Chi Lin; Peter Ansell; Monica Motwani; Shekman Wong; Huibin Yue; Lan Wang; Edward Reilly; Daniel Afar; Louie Naumovski; Ramesh K. Ramanathan
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.